Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Etrasimod

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Etrasimod, a once-daily, oral, Sphingosine-1-phosphate (S1P) receptor modulators that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable activity on S1P2,3 , is in development for the treatment of immune-mediated diseases, including ulcerative colitis.
Sandborn et al. 2023 Lancet 401: 1159-71

Etrasimod is an oral selective S1PR1, S1PR4 and S1PR5 modulator that inhibits the trafficking of lymphocytes from the lymph nodes into the blood
Wils & Peyrin-Biroulet 2023 Immunotherapy 15(5): 311-321

References (Sources)

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
Sandborn et al. 2023 Lancet 401: 1159-71
Etrasimod for the treatment of ulcerative colitis
Wils & Peyrin-Biroulet 2023 Immunotherapy 15(5): 311-321
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Etrasimod

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat

Links